surpass tirzepatide Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Tirzepatide Matches Dulaglutide in Large

Gallbladder Disease and Surgical Complications Novo Nordisk added gallbladder disease warnings to Ozempic labels in March 2022, but only after thousands of patients had already developed acute cholecystitis, gallstones, and other biliary complications requiring emergency surgery raising questions about what the company knew and when

GLP-1 medications carry a boxed warning relating to the risk of thyroid C-cell tumors observed in rodent studies and must not be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

That finding is frequently cited to support a safety claim

Typical use concentrations range from 0.3-1% depending on the formula, and this ingredient is capped at 1% int the EU

Some pharmacists struggle with making the card work